Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action.
about
Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysisRisk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.Successful drug development despite adverse preclinical findings part 2: examples.The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.PPAR Agonists and Cardiovascular Disease in Diabetes.Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes.Investigations of rodent urinary bladder carcinogens: collection, processing, and evaluation of urine and bladders.Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma AgonistsPathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) useThe role of the toxicologic pathologist in the biopharmaceutical industry.Examining the safety of PPAR agonists - current trends and future prospects.Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies.Origins of injection-site sarcomas in cats: the possible role of chronic inflammation-a review.Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?Mammalian toxicology and human exposures to the flame retardant 2,2',6,6'-tetrabromo-4,4'-isopropylidenediphenol (TBBPA): implications for risk assessment.Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.Diabetes drugs and the incidence of solid cancers: a survey of the current evidence.Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis.Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties.Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.Unique surface and internal structure of struvite crystals formed by Proteus mirabilis.Dietary ammonium chloride for the acidification of mouse urine.PPAR alpha and PPAR gamma coactivation rapidly induces Egr-1 in the nuclei of the dorsal and ventral urinary bladder and kidney pelvis urothelium of rats.Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist.Effects of thiazolidinedione in patients with active bladder cancer.Strain-related differences in urine composition of male rats of potential relevance to urolithiasis.Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event.Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer.Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar.Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: A meta-analysis.Trans-species comparison of PPAR and RXR expression by rat and human urothelial tissues.
P2860
Q27002540-31B44F3C-9943-4DE8-B82C-8D2099B6E462Q34628009-5AA6E36D-FE1B-461D-BE09-51128014F075Q34659408-B952A68E-0BFC-4C72-BBFE-7199D5A34AF9Q35603965-82E4C021-743A-467D-8544-0D0F9088D876Q36001145-4AE78DB2-FC81-4DB4-AB90-66252EC4DA36Q36013549-20AB3FE7-9464-4E95-93F5-F700CAF082B8Q36444975-90DF3440-3276-453D-9C54-1ED6D8048956Q36581133-FF031907-A4F0-4B70-BE89-CA2DE979DF55Q36800005-D34E0DBD-4195-44D4-9FC9-9E97296D6AA2Q37077098-4B56688A-DA9A-4C09-81A9-E80725F67070Q37607679-D371694F-FB9A-4D5F-8693-5537CEC53E9EQ37924048-8580307E-08D4-422A-9092-F01E67570E0CQ38058381-7848C097-B745-4876-9A9A-4D6B2166C08BQ38061184-D326E43A-80B3-4735-A7A3-FE7D90F74472Q38112125-5A799A1F-47D4-4DBB-8140-AF69BC9A7FA3Q38122640-BBEBB4B7-F513-44F6-BB13-131AB4FC81C1Q38172406-A7DB5BDB-CD17-42F8-9032-538D1A6D0152Q38222834-72912A15-7742-4F93-A9C2-466DC041D32CQ38641190-F6C1FB80-69A8-455C-ADFB-311D7C59E0C8Q38651175-2E8AFC5C-AA97-4D14-962D-B250F03FFC13Q38726257-2B619D0B-35E8-4152-BCB2-9CA65722B99CQ38818082-52FA2CE5-E40B-4E54-932F-6345E3E644FDQ40141299-B8356E83-9C6A-4D0D-8857-DBB61ABB9648Q41256018-51C1B9FB-1D75-4ACF-9F6B-D89432B10EF1Q42033047-5BAD7CBB-FF82-45C4-ADF6-39F08490DB01Q43222810-97A26076-D345-4776-8903-26B58D497C68Q43287595-78E6332B-672A-443F-8725-2774AC491588Q44375640-0A42E126-3485-404C-A113-4953B30916ACQ46043672-C243A87B-4119-4E68-BE90-635372E7FEB5Q46599209-A3F4ED19-225E-4D8B-A6B4-54E889069030Q47782346-7C231EE3-FFA5-49CD-9BE9-BCBEE3121973Q51757343-46D78CF6-3BE9-4282-85C6-05F51E2FC667Q52594525-18D601E3-BDD4-407B-9859-2B28D28E05C7Q53321831-6556F0CA-F1A8-4510-9FB1-7F8DF038B94B
P2860
Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Urothelial carcinogenesis in t ...... g event in the mode of action.
@en
Urothelial carcinogenesis in t ...... g event in the mode of action.
@nl
type
label
Urothelial carcinogenesis in t ...... g event in the mode of action.
@en
Urothelial carcinogenesis in t ...... g event in the mode of action.
@nl
prefLabel
Urothelial carcinogenesis in t ...... g event in the mode of action.
@en
Urothelial carcinogenesis in t ...... g event in the mode of action.
@nl
P2093
P2860
P1476
Urothelial carcinogenesis in t ...... g event in the mode of action.
@en
P2093
Beth E Schilling
Crystal R Waites
Jeffrey D Moehlenkamp
Lora E Arnold
Mark A Dominick
Marty Cano
Melvin R White
Samuel M Cohen
Sarah Tannehill-Gregg
Terry Van Vleet
P2860
P304
P356
10.1080/01926230601072327
P407
P577
2006-01-01T00:00:00Z